Gehrig J, Häcki W H
Schweiz Med Wochenschr. 1985 Apr 27;115(17):587-91.
In the western world esophageal cancer accounts for only 2% of all cancers. With either surgical treatment or radiotherapy, the 5-year survival rate is no higher than 10%, and with a combination of the two about 20%. Palliation is the only alternative in most cases, and aims at minimizing dysphagia. This can be achieved by endoscopic implantation of a silastic tube through the neoplastic stricture, irrespective of the general condition of the patient. The recently developed flexible Dumon set offers considerable advantages over the traditional Nottingham introducer, and allows gentle implantation even in difficult cases.
在西方世界，食管癌仅占所有癌症的2%。无论是手术治疗还是放射治疗，5年生存率都不高于10%，两者联合使用时约为20%。在大多数情况下，姑息治疗是唯一的选择，其目的是尽量减轻吞咽困难。这可以通过在内镜下将硅橡胶管植入肿瘤性狭窄部位来实现，而无需考虑患者的一般状况。最近开发的柔性杜蒙装置比传统的诺丁汉导入器具有相当大的优势，即使在困难病例中也能实现轻柔植入。
